BR112016030560A8 - parceiros de ligação específicos para epímeros de vitamina d, anticorpo e método para separar uma vitamina d epimérica de uma amostra suspeita de conter uma vitamina d epimérica - Google Patents

parceiros de ligação específicos para epímeros de vitamina d, anticorpo e método para separar uma vitamina d epimérica de uma amostra suspeita de conter uma vitamina d epimérica

Info

Publication number
BR112016030560A8
BR112016030560A8 BR112016030560A BR112016030560A BR112016030560A8 BR 112016030560 A8 BR112016030560 A8 BR 112016030560A8 BR 112016030560 A BR112016030560 A BR 112016030560A BR 112016030560 A BR112016030560 A BR 112016030560A BR 112016030560 A8 BR112016030560 A8 BR 112016030560A8
Authority
BR
Brazil
Prior art keywords
vitamin
epimeric
epimers
antibodies
antibody
Prior art date
Application number
BR112016030560A
Other languages
English (en)
Other versions
BR112016030560A2 (pt
Inventor
Manoj Sharma
Tatiana Mareeva
Yuriy Smirnov
William D Bedzyk
Zhu Teng
Tie Quan Wei
Original Assignee
Siemens Healthcare Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics Inc filed Critical Siemens Healthcare Diagnostics Inc
Publication of BR112016030560A2 publication Critical patent/BR112016030560A2/pt
Publication of BR112016030560A8 publication Critical patent/BR112016030560A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

parceiros de ligação específicos para epímeros de vitamina d. a presente invenção refere-se a anticorpos que são aumentados contra compostos de fórmula (i), em que z é um carreador imunogênico. estes compostos são capazes de se ligar especificamente a anticorpos correspondentes. os anticorpos são específicos para epímeros de vitamina d. anticorpos de acordo com os princípios descritos no presente relatório descritivo, podem ser empregados para minimizar ou eliminar reatividade cruzada de 3-epímero em ensaios para formas não epiméricas de analitos de vitamina d. a sobrestimação de analito de vitamina d não epimérico total causada pela reatividade cruzada de vitamina d de 3-epímero com um anticorpo para analito de vitamina d pode ser substancialmente evitada empregando-se, como agentes de bloqueio, anticorpos preparados contra imunógenos, que são um composto da fórmula (i), em que z é um carreador imunogênico.
BR112016030560A 2014-06-27 2015-06-22 parceiros de ligação específicos para epímeros de vitamina d, anticorpo e método para separar uma vitamina d epimérica de uma amostra suspeita de conter uma vitamina d epimérica BR112016030560A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462018012P 2014-06-27 2014-06-27
PCT/US2015/036907 WO2015200182A1 (en) 2014-06-27 2015-06-22 Binding partners specific for vitamin d epimers

Publications (2)

Publication Number Publication Date
BR112016030560A2 BR112016030560A2 (pt) 2017-08-15
BR112016030560A8 true BR112016030560A8 (pt) 2021-07-13

Family

ID=54938700

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016030560A BR112016030560A8 (pt) 2014-06-27 2015-06-22 parceiros de ligação específicos para epímeros de vitamina d, anticorpo e método para separar uma vitamina d epimérica de uma amostra suspeita de conter uma vitamina d epimérica

Country Status (8)

Country Link
US (1) US9815907B2 (pt)
EP (1) EP3172239A4 (pt)
JP (1) JP6681349B2 (pt)
KR (2) KR102309377B1 (pt)
CN (2) CN106661115A (pt)
AU (1) AU2015280292B2 (pt)
BR (1) BR112016030560A8 (pt)
WO (1) WO2015200182A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015280290B2 (en) * 2014-06-27 2019-09-19 Siemens Healthcare Diagnostics Inc. Compositions relating to vitamin D
US10191069B2 (en) 2014-12-17 2019-01-29 Siemens Healthcare Diagnostics Inc. Accurate assay measurement of hydrophobic haptenic analytes
JPWO2021100841A1 (pt) * 2019-11-22 2021-05-27

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4661408A (en) 1986-03-18 1987-04-28 E.I. Du Pont De Nemours And Company Coated chromium dioxide particles
JPH01503808A (ja) 1987-07-16 1989-12-21 イー・アイ・デユポン・ド・ネモアース・アンド・コンパニー（インコーポレイテツド） 固定化された凝集剤を用いるアフイニテイ分離
US5089390A (en) 1987-09-04 1992-02-18 Syntex (U.S.A.) Inc. 2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
US5158871A (en) 1988-02-12 1992-10-27 University Of Connecticut Method of using magnetic particles for isolating, collecting and assaying diagnostic ligates
US5147529A (en) 1988-08-10 1992-09-15 E. I. Du Pont De Nemours And Company Method for automatically processing magnetic solid phase reagents
US5151348A (en) 1988-12-23 1992-09-29 E. I. Du Pont De Nemours And Company Enzyme-linked immunoassay for measurement of cyclosporin a levels in whole blood samples
US5101015A (en) 1989-04-10 1992-03-31 Abbott Laboratories Reagents for an amphetamine-class fluorescence polarization immunoassay
US5128103A (en) 1990-12-14 1992-07-07 E. I. Du Pont De Nemours And Company Apparatus for automatically processing magnetic solid phase reagents
US5340716A (en) 1991-06-20 1994-08-23 Snytex (U.S.A.) Inc. Assay method utilizing photoactivated chemiluminescent label
US5578498A (en) 1991-05-22 1996-11-26 Behringwerke Ag Metal chelate containing compositions for use in chemiluminescent assays
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
DE69228817T2 (de) 1991-07-26 1999-09-23 Dade Chemistry Systems Inc Signalerkennungspruefung in der anwesenheit von einem suspendierten festen träger
WO1994003812A1 (en) 1992-07-31 1994-02-17 Syntex (U.S.A.) Inc. Photoactivatable chemiluminescent matrices
JPH09143154A (ja) 1995-11-20 1997-06-03 Kureha Chem Ind Co Ltd ビタミンｄ３ 誘導体の製造方法
EP0873126A4 (en) 1995-12-29 2000-04-19 A And D Assay Inc BRANDED VITAMIN COMPOUNDS AND THEIR USE
US5929049A (en) 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
US6153442A (en) 1998-05-20 2000-11-28 Dade Behring Inc. Reagents and methods for specific binding assays
US8133694B2 (en) * 1998-06-25 2012-03-13 Immundiagnostik Ag Functional vitamin D derivatives and method of determining 25-hydroxy- and 1α, 25-dihydroxy vitamin D
ATE256658T1 (de) * 1998-06-25 2004-01-15 Immundiagnostik Ges Fuer Produ Funktionelle vitamin-d-derivate und verfahren zur bestimmung von 25-hydroxy- und 1alpha,25- dihydroxy-vitamin-d
AU5473999A (en) 1998-08-11 2000-03-06 Bayer Corporation Near infrared chemiluminescent acridinium compounds and uses thereof
US6673560B1 (en) 1998-11-25 2004-01-06 Bayer Corporation Measurement of hydride using chemiluminescent acridinium compounds and applications thereof
US6783948B1 (en) 1999-07-30 2004-08-31 Bayer Corporation Chemiluminescent acridinium compounds and analogues thereof as substrates of hydrolytic enzymes
US6703248B1 (en) 1999-12-15 2004-03-09 Dade Behring Marburg Gmbh Particles for diagnostic and therapeutic use
CA2400993C (en) 2000-03-06 2011-06-07 Dade Behring Marburg Gmbh Carriers coated with polysaccharides, their preparation and use
US7319041B2 (en) 2002-09-27 2008-01-15 Siemens Medical Solutions Diagnostic Applications of acridinium compounds and derivatives in homogeneous assays
US7186518B2 (en) 2003-11-21 2007-03-06 Dade Behring Inc. Method and composition useful for determining FK 506
US20050118727A1 (en) 2003-12-01 2005-06-02 Carsten Schelp Conjugates and their use in detection methods
WO2005067673A2 (en) 2004-01-06 2005-07-28 The University Of Tennessee Research Foundation Enzymatic method to produce 7-dehydropregnenolone, vitamin d3-like compounds and derivatives thereof
US7172906B2 (en) 2004-11-16 2007-02-06 Dade Behring Inc. Reduction of non-specific binding in assays
US20100144671A1 (en) 2005-03-04 2010-06-10 Women And Infants Hospital Of Ri, Inc. Compositions and Methods for Cancer Treatment
US8785603B2 (en) * 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
US9289507B2 (en) 2012-05-17 2016-03-22 Extend Biosciences, Inc. Carriers for improved drug delivery
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
US9244083B2 (en) * 2012-11-30 2016-01-26 Siemens Healthcare Diagnostics Inc. Compositions and methods for detecting vitamin D
US9618523B2 (en) 2013-02-28 2017-04-11 Siemens Healthcare Diagnostics Inc. Methods and reagents for determining isomeric analytes
US20140308751A1 (en) 2013-04-12 2014-10-16 Siemens Healthcare Diagnostics Inc. Assays for Analyte Homologs
CN106661116B (zh) 2014-06-27 2019-04-30 西门子医疗保健诊断公司 维生素d差向异构体的测定法

Also Published As

Publication number Publication date
JP2017526630A (ja) 2017-09-14
KR20170014013A (ko) 2017-02-07
BR112016030560A2 (pt) 2017-08-15
EP3172239A1 (en) 2017-05-31
WO2015200182A1 (en) 2015-12-30
JP6681349B2 (ja) 2020-04-15
KR20180021933A (ko) 2018-03-05
EP3172239A4 (en) 2017-06-21
AU2015280292A1 (en) 2016-12-15
CN106661115A (zh) 2017-05-10
KR102309377B1 (ko) 2021-10-05
US20170121426A1 (en) 2017-05-04
AU2015280292B2 (en) 2019-08-01
CN112979818A (zh) 2021-06-18
US9815907B2 (en) 2017-11-14

Similar Documents

Publication Publication Date Title
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
PE20191708A1 (es) ANTICUERPOS DE UNION A VISTA A pH ACIDO
BR112015032445A2 (pt) componente semicondutor orgânico
BR112018075516A2 (pt) purificação de anticorpos multiespecíficos
EA201890302A1 (ru) Химерные рецепторы антигенов на основе однодоменных антител и способы их применения
BR112017005393A2 (pt) composto de fórmula i, método de preparação de um conjugado de fórmula a, conjugado de fórmula a1, composição compreendendo uma mistura dos compostos de conjugado de anticorpo-fármaco, composição farmacêutica, e uso de um conjugado ou de uma composição
WO2013096822A3 (en) Test device for optical and electrochemical assays
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
EA201692242A1 (ru) Композиции с высокой концентрацией антител
EA201400483A1 (ru) Составы собирателей и способы их применения
EA201490454A1 (ru) Тернесит в качестве активатора для латентно-гидравлических и пуццолановых веществ
BR112016024383A2 (pt) processo para a recuperação de óleo
BRPI0607323B8 (pt) composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo
EA201890080A1 (ru) Анализ модуляторов
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
BR112012015583A2 (pt) métodos para purificação de cucurbiturila
BR112022009723A2 (pt) Anticorpos específicos para cd47, pd-l1, e usos dos mesmos
EA201590459A1 (ru) Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
BR112016017764A2 (pt) anticorpo antidengue de amplo espectro
BR112016016249A2 (pt) Métodos de análise imunocromatográfica, dispositivo de análise imunocromatográfica e kit
BR112018073945A2 (pt) métodos para tratamento de miastenia grave generalizada refratária
EA201390467A1 (ru) Композиции антител и способы применения

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024007436-2 PROTOCOLO 870240032901 EM 16/04/2024 17:46.